Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386837441> ?p ?o ?g. }
- W4386837441 abstract "Abstract Background Vietnam and Saudi Arabia have high disease burden of primary hepatocellular carcinoma (HCC). Early detection in asymptomatic patients at risk for HCC is a strategy to improve survival outcomes in HCC management. GALAD score, a serum-based panel, has demonstrated promising clinical utility in HCC management. However, in order to ascertain its potential role in the surveillance of the early detection of HCC, GALAD needs to be validated prospectively for clinical surveillance of HCC (i.e., phase IV biomarker validation study). Thus, we propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients with advanced fibrosis or compensated cirrhosis, irrespective of etiologies, using semi-annual abdominal ultrasound and GALAD score for five years. Methods We plan to recruit a cohort of 1,600 patients, male or female, with advanced fibrosis or cirrhosis (i.e., F3 or F4) and MELD ≤ 15, in Vietnam and Saudi Arabia ( n = 800 each). Individuals with a liver mass ≥ 1 cm in diameter, elevated alpha-fetoprotein (AFP) (≥ 9 ng/mL), and/or elevated GALAD score (≥ -0.63) will be scanned with dynamic contrast-enhanced magnetic resonance imaging (MRI), and a diagnosis of HCC will be made by Liver Imaging Reporting and Data System (LiRADS) assessment (LiRADS-5). Additionally, those who do not exhibit abnormal imaging findings, elevated AFP titer, and/or elevated GALAD score will obtain a dynamic contrast-enhanced MRI annually for five years to assess for HCC. Only MRI nearest to the time of GALAD score measurement, ultrasound and/or AFP evaluation will be included in the diagnostic validation analysis. MRI will be replaced with an abdominal computed tomography scan when MRI results are poor due to patient conditions such as movement etc. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI will not be carried out in study sites in both countries. Bootstrap resampling technique will be used to account for repeated measures to estimate standard errors and confidence intervals. Additionally, we will use the Cox proportional hazards regression model with covariates tailored to the hypothesis under investigation for time-to-HCC data as predicted by time-varying biomarker data. Discussion The present work will evaluate the performance of GALAD score in early detection of liver cancer. Furthermore, by leveraging the prospective cohort, we will establish a biorepository of longitudinally collected biospecimens from patients with advanced fibrosis or cirrhosis to be used as a reference set for future research in early detection of HCC in the two countries. Trial registration Name of the registry: ClinicalTrials.gov Registration date: 22 April 2022 Trial registration number: NCT05342350 URL of trial registry record" @default.
- W4386837441 created "2023-09-19" @default.
- W4386837441 creator A5000313377 @default.
- W4386837441 creator A5007723039 @default.
- W4386837441 creator A5019927380 @default.
- W4386837441 creator A5026155025 @default.
- W4386837441 creator A5034114150 @default.
- W4386837441 creator A5034288602 @default.
- W4386837441 creator A5042632184 @default.
- W4386837441 creator A5042848983 @default.
- W4386837441 creator A5047576808 @default.
- W4386837441 creator A5049740864 @default.
- W4386837441 creator A5055111557 @default.
- W4386837441 creator A5058815535 @default.
- W4386837441 creator A5062963368 @default.
- W4386837441 creator A5063625018 @default.
- W4386837441 creator A5064214025 @default.
- W4386837441 creator A5065624107 @default.
- W4386837441 creator A5068454299 @default.
- W4386837441 creator A5073285204 @default.
- W4386837441 creator A5075054576 @default.
- W4386837441 creator A5075754710 @default.
- W4386837441 creator A5080221991 @default.
- W4386837441 creator A5081233409 @default.
- W4386837441 creator A5090314779 @default.
- W4386837441 creator A5090751447 @default.
- W4386837441 creator A5091667161 @default.
- W4386837441 date "2023-09-18" @default.
- W4386837441 modified "2023-09-28" @default.
- W4386837441 title "Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score" @default.
- W4386837441 cites W1999292190 @default.
- W4386837441 cites W2123730033 @default.
- W4386837441 cites W2150027485 @default.
- W4386837441 cites W2168076454 @default.
- W4386837441 cites W2481801577 @default.
- W4386837441 cites W2507979246 @default.
- W4386837441 cites W2796067155 @default.
- W4386837441 cites W2889646458 @default.
- W4386837441 cites W2957998339 @default.
- W4386837441 cites W2961505330 @default.
- W4386837441 cites W2983020673 @default.
- W4386837441 cites W3091786640 @default.
- W4386837441 cites W3204744768 @default.
- W4386837441 doi "https://doi.org/10.1186/s12885-023-11167-9" @default.
- W4386837441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37723439" @default.
- W4386837441 hasPublicationYear "2023" @default.
- W4386837441 type Work @default.
- W4386837441 citedByCount "0" @default.
- W4386837441 crossrefType "journal-article" @default.
- W4386837441 hasAuthorship W4386837441A5000313377 @default.
- W4386837441 hasAuthorship W4386837441A5007723039 @default.
- W4386837441 hasAuthorship W4386837441A5019927380 @default.
- W4386837441 hasAuthorship W4386837441A5026155025 @default.
- W4386837441 hasAuthorship W4386837441A5034114150 @default.
- W4386837441 hasAuthorship W4386837441A5034288602 @default.
- W4386837441 hasAuthorship W4386837441A5042632184 @default.
- W4386837441 hasAuthorship W4386837441A5042848983 @default.
- W4386837441 hasAuthorship W4386837441A5047576808 @default.
- W4386837441 hasAuthorship W4386837441A5049740864 @default.
- W4386837441 hasAuthorship W4386837441A5055111557 @default.
- W4386837441 hasAuthorship W4386837441A5058815535 @default.
- W4386837441 hasAuthorship W4386837441A5062963368 @default.
- W4386837441 hasAuthorship W4386837441A5063625018 @default.
- W4386837441 hasAuthorship W4386837441A5064214025 @default.
- W4386837441 hasAuthorship W4386837441A5065624107 @default.
- W4386837441 hasAuthorship W4386837441A5068454299 @default.
- W4386837441 hasAuthorship W4386837441A5073285204 @default.
- W4386837441 hasAuthorship W4386837441A5075054576 @default.
- W4386837441 hasAuthorship W4386837441A5075754710 @default.
- W4386837441 hasAuthorship W4386837441A5080221991 @default.
- W4386837441 hasAuthorship W4386837441A5081233409 @default.
- W4386837441 hasAuthorship W4386837441A5090314779 @default.
- W4386837441 hasAuthorship W4386837441A5090751447 @default.
- W4386837441 hasAuthorship W4386837441A5091667161 @default.
- W4386837441 hasBestOaLocation W43868374411 @default.
- W4386837441 hasConcept C126322002 @default.
- W4386837441 hasConcept C126838900 @default.
- W4386837441 hasConcept C143998085 @default.
- W4386837441 hasConcept C185592680 @default.
- W4386837441 hasConcept C188816634 @default.
- W4386837441 hasConcept C2777214474 @default.
- W4386837441 hasConcept C2778019345 @default.
- W4386837441 hasConcept C2780140570 @default.
- W4386837441 hasConcept C2781197716 @default.
- W4386837441 hasConcept C55493867 @default.
- W4386837441 hasConcept C71924100 @default.
- W4386837441 hasConcept C72563966 @default.
- W4386837441 hasConcept C90924648 @default.
- W4386837441 hasConceptScore W4386837441C126322002 @default.
- W4386837441 hasConceptScore W4386837441C126838900 @default.
- W4386837441 hasConceptScore W4386837441C143998085 @default.
- W4386837441 hasConceptScore W4386837441C185592680 @default.
- W4386837441 hasConceptScore W4386837441C188816634 @default.
- W4386837441 hasConceptScore W4386837441C2777214474 @default.
- W4386837441 hasConceptScore W4386837441C2778019345 @default.
- W4386837441 hasConceptScore W4386837441C2780140570 @default.
- W4386837441 hasConceptScore W4386837441C2781197716 @default.
- W4386837441 hasConceptScore W4386837441C55493867 @default.
- W4386837441 hasConceptScore W4386837441C71924100 @default.
- W4386837441 hasConceptScore W4386837441C72563966 @default.